Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: Clinical experience in the last 5 years

Transplantation Proceedings

Volumn 42, Issue 8, 2010, Pages 2859-2860

  Sola, E ^a   Lopez, V ^a   Gutierrez, C ^a   Cabello, M ^a   Burgos, D ^a   Molina, M G ^a   Hernandez, D ^a  

^a HU Carlos Haya   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ADULT; AGED; APHTHOUS STOMATITIS; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY TRANSPLANTATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RETROSPECTIVE STUDY; SIDE EFFECT; SKIN MANIFESTATION; SKIN TUMOR;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 77958576736     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.07.062     Document Type: Article

References (4)

1. F. Dieckmann, and J.M. Campistol Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks Nephrol Dial Transplant 21 2006 562
2. J.M. Campistol, J. Albanell, and W. Arns Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance Nephrol Dial Transplant 22 2007 i36
3. V. Lopez, C. Gutierrez, and M. Cabello Conversion to sirolimus in posttransplant renal neoplasms Transplant Proc 39 2007 2264
4. A.V. Mulay, S. Cockfield, and R. Stryker Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: a systematic review of the evidence Transplantation 82 2006 1153